Abstract: An agent for removing malodor from a painting booth includes a volatile organic compound (VOC) degrading microorganism and a volatile fatty acid (VFA) degrading microorganism. The VOC degrading microorganism is configured to degrade VOC. The VFA degrading microorganism is configured to degrade VFA generated when the VOC is degraded. A method of removing malodor is also disclosed.

Abstract: An agent for removing malodor from a painting booth includes a volatile organic compound (VOC) degrading microorganism and a volatile fatty acid (VFA) degrading microorganism. The VOC degrading microorganism is configured to degrade VOC. The VFA degrading microorganism is configured to degrade VFA generated when the VOC is degraded.A method of removing malodor is also disclosed.

Abstract: An agent for removing malodor from a painting booth includes a volatile organic compound (VOC) degrading microorganism and a volatile fatty acid (VFA) degrading microorganism. The VOC degrading microorganism is configured to degrade VOC. The VFA degrading microorganism is configured to degrade VFA generated when the VOC is degraded.A method of removing malodor is also disclosed.

Abstract: An agent for removing malodor from a painting booth includes a volatile organic compound (VOC) degrading microorganism and a volatile fatty acid (VFA) degrading microorganism. The VOC degrading microorganism is configured to degrade VOC. The VFA degrading microorganism is configured to degrade VFA generated when the VOC is degraded. A method of removing malodor is also disclosed.

Abstract: The present invention relates to a recording medium having data recorded therein in a data file format structure for visualization of large capacity CFD parallel data and to a method for generating said data file format structure, in which the large capacity data is generated and stored or recorded in the data file format structure of a structured grid or an unstructured grid in processing large capacity CFD data in parallel to each other and visualizing the data.

Abstract: A non-aqueous electrolyte solution includes an electrolyte solution including an amide compound and a lithium salt, and a dinitrile compound substituted by a hetero atom at a main chain, and a lithium secondary battery includes the non-aqueous electrolyte solution. By using the non-aqueous electrolyte solution, a lithium secondary battery having an improved swelling phenomenon and an increased charging/discharging performance may be provided.

Abstract: A method of preparing a tricyanoalkoxy alkane compound is disclosed. The tricyanoalkoxy alkane compound is prepared by reacting an alcohol compound including at least three hydroxyl groups and a nitrile compound in the presence of a potassium alkoxide catalyst. A non-aqueous electrolyte solution comprising the tricyanoalkoxy alkane compound and a lithium secondary battery also are disclosed. The swelling of the battery may be prevented.

Abstract: A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Abstract: A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Abstract: A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Abstract: A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Abstract: A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Abstract: An OCD measurement equipment, including a tunable laser system, and a method of measuring the CD of patterns formed on a substrate. A light source optical system emits light which wavelength changes over time. A projector optical system projects the light emitted from the light source optical system on the substrate. A substrate support unit supports the substrate. An image relay optical system relays light reflected by the substrate. An image detection optical system detects the light relayed by the image relay optical system using a detector which detects the spatial distribution of the light.